2/17
08:00 am
ttrx
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
High
Report
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
2/9
08:42 am
ttrx
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences [Yahoo! Finance]
Low
Report
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences [Yahoo! Finance]
2/9
08:00 am
ttrx
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
Low
Report
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
1/20
08:02 am
ttrx
Turn Therapeutics (NASDAQ:TTRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $8.00 price target on the stock.
Low
Report
Turn Therapeutics (NASDAQ:TTRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $8.00 price target on the stock.
1/12
08:05 am
ttrx
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
1/7
04:05 pm
ttrx
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
Low
Report
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
1/6
04:10 pm
ttrx
Turn Therapeutics (NASDAQ:TTRX) is now covered by analysts at
Weiss Ratings. They set a "sell (e-)" rating on the stock.
Low
Report
Turn Therapeutics (NASDAQ:TTRX) is now covered by analysts at
Weiss Ratings. They set a "sell (e-)" rating on the stock.
12/31
06:48 am
ttrx
Turn Therapeutics (NASDAQ:TTRX) was upgraded by analysts at D Boral Capital to a "strong-buy" rating.
Medium
Report
Turn Therapeutics (NASDAQ:TTRX) was upgraded by analysts at D Boral Capital to a "strong-buy" rating.
12/31
06:48 am
ttrx
Turn Therapeutics (NASDAQ:TTRX) was upgraded by analysts at D Boral Capital to a "strong-buy" rating.
Medium
Report
Turn Therapeutics (NASDAQ:TTRX) was upgraded by analysts at D Boral Capital to a "strong-buy" rating.
12/29
08:00 am
ttrx
Turn Therapeutics (NASDAQ:TTRX) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $8.00 price target on the stock.
High
Report
Turn Therapeutics (NASDAQ:TTRX) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $8.00 price target on the stock.